153 related articles for article (PubMed ID: 26165588)
1. Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.
Moreira DM; Bostwick DG; Andriole GL; Peterson BL; Cohen HJ; Castro-Santamaria R; Freedland SJ
J Urol; 2015 Nov; 194(5):1241-6. PubMed ID: 26165588
[TBL] [Abstract][Full Text] [Related]
2. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Gerber L; Muller RL; Andriole GL; Castro-Santamaria R; Freedland SJ
Cancer; 2014 Jan; 120(2):190-6. PubMed ID: 24323568
[TBL] [Abstract][Full Text] [Related]
3. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
[TBL] [Abstract][Full Text] [Related]
4. Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study.
Moreira DM; Fleshner NE; Freedland SJ
J Urol; 2015 Nov; 194(5):1258-63. PubMed ID: 25988518
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
6. Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study.
Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate; 2015 Sep; 75(13):1492-8. PubMed ID: 26184556
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations.
Moreira DM; Andriole GL; Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ
World J Urol; 2017 Oct; 35(10):1525-1530. PubMed ID: 28396999
[TBL] [Abstract][Full Text] [Related]
8. Extent of Baseline Prostate Atrophy Is Associated With Lower Incidence of Low- and High-grade Prostate Cancer on Repeat Biopsy.
Freitas DM; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
Urology; 2017 May; 103():161-166. PubMed ID: 28024967
[TBL] [Abstract][Full Text] [Related]
9. The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens.
Moreira DM; de O Freitas DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):413-417. PubMed ID: 28585572
[TBL] [Abstract][Full Text] [Related]
10. Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy.
Moreira DM; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):106-112. PubMed ID: 29203895
[TBL] [Abstract][Full Text] [Related]
11. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
Quentin M; Blondin D; Arsov C; Schimmöller L; Hiester A; Godehardt E; Albers P; Antoch G; Rabenalt R
J Urol; 2014 Nov; 192(5):1374-9. PubMed ID: 24866597
[TBL] [Abstract][Full Text] [Related]
13. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
Fleshner NE; Lucia MS; Egerdie B; Aaron L; Eure G; Nandy I; Black L; Rittmaster RS
Lancet; 2012 Mar; 379(9821):1103-11. PubMed ID: 22277570
[TBL] [Abstract][Full Text] [Related]
14. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
15. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
16. The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens.
Freitas DMO; Andriole GL; Castro-Santamaria R; Freedland SJ; Moreira DM
Scand J Urol; 2018; 52(5-6):328-332. PubMed ID: 30762450
[TBL] [Abstract][Full Text] [Related]
17. Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
Naha U; Nickel JC; Andriole GL; Freedland SJ; Moreira DM
J Urol; 2021 Mar; 205(3):755-760. PubMed ID: 33080149
[TBL] [Abstract][Full Text] [Related]
18. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
20. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.
Gittelman MC; Hertzman B; Bailen J; Williams T; Koziol I; Henderson RJ; Efros M; Bidair M; Ward JF
J Urol; 2013 Jul; 190(1):64-9. PubMed ID: 23416644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
